Menu

CME Corner

This activity has expired. CME/CE credit is no longer available and the following content may not be available or may not be up-to-date. For a list of current activities that offer CME/CE credit, click here.

Program Detail

Release Date: October-30-09
Credit Expiration Date: October-30-10

Faculty

James F. Donohue, MD
Professor of Medicine
Chief, Division of Pulmonary and Critical Care Medicine
University of North Carolina at Chapel Hill
Chapel Hill, NC

Douglas W. Mapel, MD, MPH, FCCP
Medical Director, Lovelace Clinic Foundation
Albuquerque, NM

Credit Hours

1.0

Medium

e-Monograph

Program Description

Uncontrolled and chronic obstruction pulmonary disease (COPD) are on the rise in the United States, and optimal management of these chronic lung diseases continues to challenge clinicians. Patients with these highly prevalent conditions often may receive less-than-optimal medical care. Even though practice guidelines for both asthma and COPD have been available for many years and are updated regularly, many patients with asthma or COPD do not receive adequate treatment as recommended by these evidence-based guidelines. Both asthma and COPD have a significant impact on quality of life and may lead to premature death. Improving the management of patients with asthma and COPD can ultimately improve clinical outcomes for these patients. This monograph offers an overview of asthma and COPD and describes current treatment options, management techniques, and emerging therapies for these two diseases.

Program Developer/Facilitator


.

Target Audience

This educational activity is designed to meet the needs of pulmonologists, allergy/immunology specialists, primary care providers, nurse practitioners/advance practice nurses, and other health care providers with an interest in the treatment of chronic obstructive pulmonary disease or asthma.

Learning Objectives

Upon completion of this educational activity, the participant should be able to:

  1. Explain the rationale for the recent changes to both asthma and COPD treatment guidelines.
  2. Compare the benefits of ICS, LABA, and combination therapies with their associated risk profiles.
  3. Identify the appropriate patient groups who may benefit from ICS, LABA, and combination therapies.
  4. Describe the disparities in asthma and COPD care in older adults and minorities.

Disclosures

It is the policy of AKH Inc. to ensure independence, balance, objectivity, scientific rigor, and integrity in all of its continuing education activities. The faculty must disclose to the participants any significant relationships with commercial interests whose products or devices may be mentioned in the activities or with the commercial supporter of these continuing education activities. Identified conflict of interest is resolved by AKH prior to accreditation of the activities. AKH planners and reviewers have no relevant financial relationships to disclose.

James F. Donohue, MD, discloses that he has served as a consultant to AstraZeneca, Boehringer Ingelheim Pharmaceuticals, Inc., DEY, L.P., Forest Laboratories, Inc., GlaxoSmithKline, Novartis, Nycomed, and Sepracor Inc. Dr. Donohue also discloses that he has served on the speakers bureaus of AstraZeneca Pharmaceuticals LP, Boehringer Ingelheim Pharmaceuticals, Inc., and GlaxoSmithKline. He has received research support from Boehringer Ingelheim Pharmaceuticals, Inc., Centocor, and Novartis.

Douglas W. Mapel, MD, MPH, FCCP, discloses that he has received research support from and served as a consultant to GlaxoSmithKline and Pfizer Pharmaceuticals.

Credit Statements

PHYSICIANS: This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of AKH Inc. and Medical Communications Media, Incorporated. AKH Inc. is accredited by the ACCME to provide continuing medical education for physicians.
AKH Inc. designates this educational activity for a maximum of 1 AMA PRA Category 1 CreditTM. Physicians should only claim credit commensurate with the extent of their participation in the activity.

NURSES: AKH Inc. is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s COA.
AKH Inc. designates this educational activity for 1 contact hour (0.1 CEU). Accreditation applies solely to educational activities and does not imply approval or endorsement of any commercial product by the ANCC-COA.

Commercial Support Statements

.

Certificate Fee

$0.00

Disclaimer

The opinions expressed in these educational activities are those of the faculty and do not necessarily reflect the opinions or recommendations of their affiliated institutions, the publisher, AKH Inc., or AstraZeneca. Any medications, diagnostic procedures, or treatments discussed by the program presenters should not be used by clinicians or other health care professionals without first evaluating their patients’ conditions, considering possible contraindications or risks, reviewing any applicable manufacturer’s product information, and comparing any therapeutic approach with the recommendations of other authorities.

By clicking START PROGRAM I acknowledge that I have read the CME/CE information above.

Main Menu
EDITOR'S PICKS